Abbreviations: DEX ¼ dexamethasone; HD-CY ¼ high-dose cyclophosphamide; IVIG ¼ intravenous immunoglobulin; IVMD ¼ intravenous melphalan and dexamethasone; MP ¼ melphalan and prednisolone; ND ¼ not done; PSL ¼ prednisolone; Thal ¼ thalidomide; VAD ¼ vincristine, doxorubicin and dexamethasone; VEGF ¼ vascular endothelial growth factor. *The period from onset of the disease to PBSC collection.
Polyneuropathy, organomegaly, endocrinopathy, M-protein, skin abnormalities (POEMS) syndrome is a rare plasma cell dyscrasia defined by the presence of peripheral neuropathy, monoclonal plasma cells and paraneoplastic features, such as skin changes and generalized edema. 1 Although the pathogenesis of this syndrome is unclear, it is believed to be related to excessive production of vascular endothelial growth factor (VEGF), probably secreted by clonal plasma cells or abnormally released by activated platelets. 2 Increased VEGF production appears to cause most disease features such as polyneuropathy, by inducing angiogenesis and microvascular hyperpermeability.
In the past decade, treatment of POEMS syndrome has expanded to include high-dose (HD) melphalan, followed by autologous PBSC transplantation (ASCT) and novel agents, including thalidomide, lenalidomide and bortezomib. Numerous reports have demonstrated that ASCT is the most effective therapy for these patients, causing improvement in multiple symptoms and VEGF levels. 3 --7 However, collection of PBSCs in patients with POEMS syndrome is challenging, and such patients are at a higher risk than those with lymphoma or myeloma because of poor performance status (PS), morbidities associated with uncontrollable effusions or splenomegaly, and high serum VEGF levels. As the appropriate timing and factors associated with the efficiency of PBSC collection are unclear, we analyzed the factors affecting the efficiency of cell collection and engraftment in POEMS syndrome patients.
Subjects included 19 patients with POEMS syndrome, aged o65 years, without severe organ failure or active infection who underwent PBSC collection at Chiba University Hospital between December 2003 and November 2009. PBSC mobilization was performed either with 4 g/m 2 CY (HD-CY), followed by granulocyte G-CSF administration or G-CSF alone (5 mg/kg for 5 days). ASCT was performed with 200 mg/m 2 melphalan, with the dose reduced to 140 mg/m 2 in patients with PS 4. The effects of the harvest regimen, degree of splenomegaly, platelet count and VEGF levels on the efficacy of PBSC collection were evaluated. The number of 0.5 mm thick spleen slices obtained by CT was calculated to evaluate the spleen size.
Patient characteristics are shown in Table 1 . Median age was 52 years (range; 34 --64 years) and median time from onset of POEMS syndrome to PBSC collection was 14 months (range, 3 --110 months). In all 12 patients received HD-CY and 9 received G-CSF alone for mobilization. The median number of total CD34 þ cells was 4.56 Â 10 6 /kg (range, 0 --9.60 Â 10 6 /kg), with the median number of cells in 100 mL of apheresis product in the HD-CY /kg (range; 0 --6.9 Â 10 6 /kg) vs 0.73 Â 10 6 /kg (range, 0.1 --2.1 Â 10 6 /kg), P ¼ 0.023; Figure 1A) . However, the proportion of patients with 42 Â 10 6 cells/kg was not significantly different between the two groups (P ¼ 0.203).
We examined the relationship between the efficiency of PBSC collection, and serum VEGF levels and platelet counts. Median serum VEGF level and platelet counts before PBSC collection were 1370 pg/mL (range; 25 --8160 pg/mL, n ¼ 13) and 19.4 Â 10 4 /mL (range; 4.6 --66.4 Â 10 4 /mL), respectively. There was no correlation between VEGF levels or platelet counts and efficacy of PBSC collection. Conversely, splenomegaly was associated with a decrease in the efficacy of PBSC collection in the HD-CY (r ¼ À0.462) and G-CSF (r ¼ À0.435) groups ( Figure 1B) . We could not harvest sufficient PBSCs in two patients (no. 7 and 19) with severe splenomegaly (24 and 22 slices, respectively).
A total of 17 patients underwent ASCT with a median infused CD34 þ cell dose of 2.3 Â 10 6 /kg (range, 1.4 --4.8 Â 10 6 /kg), and all patients were engrafted. The median time of neutrophil, platelet, and reticulocyte engraftment was 13 (range, 9 --17 days), 13.5 (range, 8 --31days) and 17 days (range, 13 --36 days), respectively. The time of engraftment did not differ between the HD-CY (n ¼ 10) and G-CSF (n ¼ 6) groups. Three patients (17.6%) developed engraftment syndrome requiring steroid treatment and one (no. 15) required mechanical ventilation and hemodialysis.
Splenomegaly was associated with a decrease in the efficacy of PBSC collection in the HD-CY and G-CSF groups. We failed to collect stem cells in 2 patients with severe splenomegaly, although patient no. 9 yielded sufficient PBSCs after improvement in splenomegaly by thalidomide þ dexamethasone. These results suggest that controlling disease status is important to collect sufficient PBSCs. As melpharan is potentially deleterious to stem cells, it should not be used as the initial treatment before PBSC harvest, with thalidomide or lenalidomide combined with dexamethasone being the treatment of choice to control pleural effusion, ascites and serum VEGF levels.
Serum VEGF levels at the time of PBSC collection did not influence the efficiency of collection. This suggests that VEGF level is not a factor for predicting the optimal timing of PBSC collection. Although a correlation between disease course and VEGF levels has been reported, 8 Goto et al. 9 showed a discrepancy between disease activity and VEGF levels in POEMS syndrome patients. Because of the relatively small number of patients in our study, further evaluation is required to determine whether a relationship exists between the efficiency of PBSC collection and VEGF levels.
In the present study, PBSCs were collected using either HD-CY with G-CSF or G-CSF alone. We were able to collect a significantly higher number of CD34 þ cells in the HD-CY group than in the G-CSF group. However, there was no significant difference between the two groups in the number of patients who yielded 41 Â 10 6 /kg of PBSCs in 100 mL of apheresis product on the first day of collection. This is considered a sufficient number for a single ASCT.
In summary, we evaluated factors associated with the efficacy of stem cell collection in patients with POEMS syndrome. Splenomegaly may be a predictive factor for poor mobilization. G-CSF monotherapy is a suitable regimen for safe and efficient PBSC collection. Suitable prior therapy should be performed in patients considered poor mobilizers in order to establish a treatment strategy that includes optimal timing for effective and safe PBSC collection leading to a successful outcome in ASCT. 
